Categories: CancerHealthcareNews

Vor Bio to Participate in the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1×1 investor meetings at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.

Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Fireside Chat: Wednesday, February 12th at 12:00pm ET
Location: Virtual

A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com

Staff

Recent Posts

MDaudit Recognized as One of Modern Healthcare’s Best in Business

WELLESLEY, MA / ACCESS Newswire / January 12, 2026 / MDaudit, an award-winning cloud-based continuous…

3 hours ago

MDaudit Recognized as One of Modern Healthcare’s Best in Business

WELLESLEY, MA / ACCESS Newswire / January 12, 2026 / MDaudit, an award-winning cloud-based continuous…

3 hours ago

US Med-Equip Recognized as One of Modern Healthcare’s Best in Business

Fast-Growing Rental Company Honored for Supply Chain Excellence Supporting Hospitals HOUSTON, TEXAS / ACCESS Newswire…

3 hours ago

US Med-Equip Recognized as One of Modern Healthcare’s Best in Business

Fast-Growing Rental Company Honored for Supply Chain Excellence Supporting Hospitals HOUSTON, TEXAS / ACCESS Newswire…

3 hours ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing…

3 hours ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing…

3 hours ago